Biogen Pharmachem Industries Past Earnings Performance
Past criteria checks 0/6
Biogen Pharmachem Industries has been growing earnings at an average annual rate of 45.3%, while the Capital Markets industry saw earnings growing at 29.6% annually. Revenues have been declining at an average rate of 1.8% per year.
Key information
45.3%
Earnings growth rate
60.5%
EPS growth rate
Capital Markets Industry Growth | 20.7% |
Revenue growth rate | -1.8% |
Return on equity | -0.6% |
Net Margin | 24.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biogen Pharmachem Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | -15 | -4 | 0 | 0 |
30 Jun 24 | 15 | 14 | 0 | 0 |
31 Mar 24 | 8 | 19 | 1 | 0 |
31 Dec 23 | 10 | 10 | 2 | 0 |
30 Sep 23 | 12 | 12 | 2 | 0 |
30 Jun 23 | 25 | 25 | 2 | 0 |
31 Mar 23 | 3 | 5 | 2 | 0 |
31 Dec 22 | 10 | 4 | 0 | 0 |
30 Sep 22 | 7 | 1 | 0 | 0 |
30 Jun 22 | -3 | -18 | 1 | 0 |
31 Mar 22 | 25 | 0 | 1 | 0 |
31 Dec 21 | 61 | 8 | 0 | 0 |
30 Sep 21 | 39 | -14 | 0 | 0 |
30 Jun 21 | 29 | -14 | 0 | 0 |
31 Mar 21 | 16 | -16 | 0 | 0 |
31 Dec 20 | 0 | -23 | 0 | 0 |
30 Sep 20 | 0 | -1 | 0 | 0 |
30 Jun 20 | 0 | -1 | 0 | 0 |
31 Mar 20 | 0 | -1 | 0 | 0 |
31 Dec 19 | 5 | 0 | 0 | 0 |
30 Sep 19 | 9 | 0 | 0 | 0 |
30 Jun 19 | 9 | 0 | 0 | 0 |
31 Mar 19 | 9 | 0 | 0 | 0 |
31 Dec 18 | 5 | -65 | 0 | 0 |
30 Sep 18 | 0 | -66 | 0 | 0 |
30 Jun 18 | 0 | -67 | 0 | 0 |
31 Mar 18 | 0 | -66 | 0 | 0 |
31 Dec 17 | 0 | -1 | 1 | 0 |
30 Sep 17 | 0 | -1 | 1 | 0 |
30 Jun 17 | 0 | -1 | 1 | 0 |
31 Mar 17 | 0 | -1 | 0 | 0 |
31 Dec 16 | 0 | 0 | 0 | 0 |
30 Sep 16 | 0 | 0 | 0 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
31 Mar 16 | 0 | 0 | 0 | 0 |
31 Dec 15 | 0 | -1 | 0 | 0 |
30 Sep 15 | 0 | -1 | 0 | 0 |
30 Jun 15 | 0 | -1 | 0 | 0 |
31 Mar 15 | 0 | -1 | 0 | 0 |
31 Dec 14 | 0 | -1 | 0 | 0 |
30 Sep 14 | 0 | -1 | 0 | 0 |
30 Jun 14 | 0 | -1 | 0 | 0 |
31 Mar 14 | 0 | -1 | 0 | 0 |
Quality Earnings: 531752 is currently unprofitable.
Growing Profit Margin: 531752 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531752 is unprofitable, but has reduced losses over the past 5 years at a rate of 45.3% per year.
Accelerating Growth: Unable to compare 531752's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 531752 is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (50.1%).
Return on Equity
High ROE: 531752 has a negative Return on Equity (-0.64%), as it is currently unprofitable.